DOCSLIB.ORG

Diagnosed Cases of Rare Diseases at CENTOGENE January 2012 to June 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diagnosed Cases of Rare Diseases at CENTOGENE January 2012 to June 2016 CENTOGENE Report: Diagnosed cases of rare diseases at CENTOGENE January 2012 to June 2016 Elucidating the basis for the link between the clinical phenotype and At CENTOGENE we are committed to helping you with your genotype correlation, and the factors contributing to reveal disease medical needs. frequency, provide new insights into the genetics, pathophysiology and therapeutic options available for rare diseases. Analyzing samples We are pleased to present our analysis from January 2012 to from over 100 countries worldwide allows us to understand ethnic June 2016 of diagnosed cases at CENTOGENE. In that period, differences that are important for a comprehensive test interpretation. CENTOGENE has confirmed more than 21,077 cases. With the help of our unique, multi-ethnic CENTOGENE mutation CENTOGENE’s American and European accreditations (CAP, CLIA database CentoMD® we are able to help you detecting the right and ISO) confirm our highest quality standards for diagnostic genotype/phenotype correlation as well as provide differential testing and medical reporting. diagnostic approaches. Our partners worldwide Samples ■ > 2000 ■ 501 – 2000 ■ 101 – 500 ■ 51 – 100 ■ < 50 June 2015 to May 2016 › Contact details CENTOGENE AG Customer Service Schillingallee 68 Phone: +49 (0)381 203 652- 222 18057 Rostock, Germany Fax: +49 (0)381 203 652-119 www.centogene.com E-Mail: [email protected] CLIA #99D2049715 V6_August2016 Confirmed cases/carriers by disease category Diagnosed Diagnosed cases/ cases/ Disease carriers Disease carriers 01/2012 - 01/2012 - 06/2016 06/2016 OMIM Name TOTAL OMIM Name TOTAL 01. Metabolic disorders 311250 Ornithine transcarbamylase deficiency 28 TOTAL 8233 243500 Isovaleric acidemia 27 301500 Fabry Disease 2354 235200 Hemochromatosis 26 230800 Gaucher Disease 578 228000 Farber lipogranulomatosis 26 309900 Mucopolysaccharidosis II (Hunter syndrome) 565 610921 Surfactant metabolsim dysfunction, pulmonary, 3 25 232300 Glycogen storage disease II (Pompe) 377 212140 Carnitine deficiency, systemic primary 25 257220 Niemann-Pick disease, type C1 198 276700 Tyrosinemia, type I 24 253000 Mucopolysaccharidosis IVA 177 230400 Galactosemia 24 607015 Mucopolysaccharidosis Ih/s 163 236792 L-2-hydroxyglutaric aciduria 24 219700 Cystic fibrosis 134 609015 Trifunctional protein deficiency 23 250100 Metachromatic leukodystrophy 122 143890 Hypercholesterolemia, familial 22 253200 Mucopolysaccharidosis type VI (Maroteaux-Lamy) 118 272200 Multiple sulfatase deficiency 22 201910 Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 117 232220 Glycogen storage disease Ib 22 245200 Krabbe disease 82 253220 Mucopolysaccharidosis VII 21 606054 Propionicacidemia 80 218030 Apparent mineralocorticoid excess 21 277900 Wilson disease 75 601847 Cholestasis, progressive familial intrahepatic, 2 21 257200 Niemann-Pick disease, type A 74 602347 Cholestasis, progressive familial intrahepatic, 3 21 252900 Mucopolysaccharidosis type IIIA (Sanfilippo A) 72 237300 Carbamoylphosphate synthetase I deficiency 21 253260 Biotinidase deficiency 59 246450 HMG-CoA lyase deficiency 21 248600 Maple syrup urine disease, type Ia 59 210210 3-Methylcrotonyl-CoA carboxylase 2 deficiency 20 230500 GM1-gangliosidosis, type I 52 272300 Sulfite oxidase deficiency 20 268800 Sandhoff disease, infantile, juvenile, and adult forms 50 261630 Hyperphenylalaninemia, BH4-deficient, C 19 259900 Hyperoxaluria, primary, type 1 49 256731 Ceroid lipofuscinosis, neuronal, 5 19 248600 Maple syrup urine disease, type Ib 48 224120 Anemia, congenital dyserythropoietic, type I 18 201475 Very long Chain acyl-CoA dehydrogenase deficiency 46 203400 Hypoaldosteronism, congenital, due to CMO I deficiency 18 219800 Cystinosis nephropathic 46 614096 Combined oxidative phosphorylation deficiency 8 18 252920 Mucopolysaccharidosis type IIIB (Sanfilippo B) 46 266150 Pyruvate carboxylase deficiency 18 266200 Pyruvate kinase deficiency 43 204200 Ceroid lipofuscinosis, neuronal, 3 18 207900 Argininosuccinic aciduria 42 607625 Niemann-pick disease, type C2 17 231680 Glutaric acidemia 42 252930 Mucopolysaccharidosis type IIIC (Sanfilippo C) 17 232600 Glycogen storage disease type V/McArdle disease 40 255120 CPT deficiency, hepatic, type IA 16 251000 Methylmalonic aciduria, mut(0) type 39 600143 Ceroid lipofuscinosis, neuronal, 8 15 204500 Ceroid lipofuscinosis, neuronal, 2 38 212065 Congenital disorder of glycosylation, type Ia 15 231670 Glutaricaciduria, type I 36 229700 Fructose-1,6-bidphosphatase deficiency 15 246900 Dihydrolipoamide dehydrogenase deficiency / MSUD III 36 176000 Porphyria, acute intermittent 15 272800 Tay-Sachs disease 34 256450 Hyperinsulinemic hypoglycemia, familial 1 15 261600 Phenylketonuria 34 306000 Glycogen storage disease, type IXa1/a2 15 252500 Mucolipidosis II alpha/beta 34 227810 Fanconi-Bickel syndrome 14 215700 Citrullinemia 34 613490 Alpha-1-antitrypsin deficiency 14 201450 Medium chain acyl-CoA dehydrogenase deficiency 32 256550 Neuraminidase deficiency 14 227650 Fanconi anemia, complementation group A 32 230000 Fucosidosis 14 232400 Glycogen storage disease III 31 203750 Alpha-methylacetoacetic aciduria 14 601780 Ceroid lipofuscinosis, neuronal, 6 30 615574 Asparagine synthetase deficiency 14 248600 Maple syrup urine disease, type II 30 256540 Galactosialidosis 14 249100 Familial Mediterranean fever, AR 29 232500 Glycogen storage disease IV 13 277400 Methylmalonic aciduria and homocystinuria, cblC type 29 610951 Ceroid lipofuscinosis, neuronal, 7 13 232200 Glycogen storage disease Ia 29 304800 Diabetes insipidus, nephrogenic 13 2 Diagnosed Diagnosed cases/ cases/ Disease carriers Disease carriers 01/2012 - 01/2012 - 06/2016 06/2016 OMIM Name TOTAL OMIM Name TOTAL 606003 Transaldolase deficiency 13 222700 Lysinuric protein intolerance 6 612736 Guanidinoacetate methyltransferase deficiency 12 614924 Combined oxidative phosphorylation deficiency 12 6 253010 Mucopolysaccharidosis type IVB (Morquio) 12 136120 Fish-eye disease 6 614576 Congenital disorder of glycosylation, type IIl 12 610549 Diabetes mellitus, insulin-resistant, with acanthosis nigricans 6 125851 Maturity-onset diabetes of the young, type 2 12 201810 3-beta-hydroxysteroid dehydrogenase, type II, deficiency 6 229600 Fructose intolerance 12 614922 Combined oxidative phosphorylation deficiency 11 6 278000 Wolman disease 12 300816 Combined oxidative phosphorylation deficiency 6 6 251110 Methylmalonic aciduria, cblB type 11 615317 Multiple mitochondrial dysfunctions syndrome 6 607616 Niemann-Pick disease, type B 11 218800 Crigler-Najjar syndrome, type I 6 261750 Glycogen storage disease IXb 10 603147 Congenital disorder of glycosylation, type Ic 6 610832 Fanconi anemia, complementation group N 10 601110 Congenital disorder of glycosylation, type Id 6 609016 long-chain 3-hydroxyl-CoA dehydrogenase deficiency 10 300884 Congenital disorder of glycosylation, type Is 5 614265 Combined malonic and methylmalonic aciduria 10 271980 Succinic semialdehyde dehydrogenase deficiency 5 238600 Hyperlipoproteinemia, type 1 9 262190 Rabson-Mendenhall syndrome 5 232700 Glycogen storage disease VI 9 142680 Periodic fever, familial 5 245050 Succinyl CoA:3-oxoacid CoA transferase deficiency 9 601346 Martinez-Frias syndrome 5 224100 Anemia, dyserythropoietic congenital, type II 9 204750 2-aminoadipic 2-oxoadipic aciduria 5 602390 Hemochromatosis, type 2A 9 300559 Muscle glycogenosis 5 614082 Fanconi anemia, complementation group G 9 261680 Phosphoenolpyruvate carboxykinase-1, cytosolic, deficiency 5 614300 Hypermethioninemia due to adenosine kinase deficiency 9 609924 Aminoacylase 1 deficiency 5 241510 Hypophosphatasia, childhood 8 603467 Fanconi anemia, complementation group F 5 246200 Donohue syndrome 8 613559 Combined oxidative phosphorylation deficiency 7 5 137920 Maturity-onset diabetes of the young type 5 8 614372 Mannose-Binding Protein Deficiency 5 125850 MODY, type I 8 608540 Congenital disorder of glycosylation, type Ik 5 248190 Hypomagnesemia 5, renal, with ocular involvement 8 614307 Alpha-methylacyl-CoA racemase deficiency 5 252150 Molybdenum cofactor deficiency 8 248250 Hypomagnesemia 3, renal 5 248360 Malonyl-CoA decarboxylase deficiency 8 210200 3-Methylcrotonyl-CoA carboxylase 1 deficiency 5 3-methylglutaconic aciduria with deafness, encephalopathy, and 227646 Fanconi anemia, complementation group D2 5 614739 8 Leigh-like syndrome 227645 Fanconi anemia, complementation group C 5 252940 Mucopolysaccharidosis type IIID 8 600496 Maturity-onset diabetes of the young type 3 5 211600 Cholestasis, Progressive Familial Intrahepatic, 1 8 245349 Lacticacidemia due to PDX1 deficiency 5 251100 Methylmalonic aciduria, cblA type 7 261640 Hyperphenylalaninemia, BH4-deficient, A 4 605724 Fanconi anemia, complementation group D1 7 220110 Mitochondrial complex IV deficiency 4 600649 CPT deficiency, hepatic, type II 7 300352 Cerebral creatine deficiency syndrome 1 4 256730 Ceroid lipofuscinosis, neuronal, 1 7 607398 Glucocorticoid deficiency 2 4 613646 Methylmalonic aciduria due to transcobalamin receptor defect 7 613027 Glycogen storage disease IXc 4 258900 Orotic aciduria 7 176200 Porphyria variegata 4 613280 Hypermanganesemia with dystonia, polycythemia, and cirrhosis 7 205400 Tangier disease 4 146300 Hypophosphatasia, adult 7 248510 Mannosidosis, Beta A, Lysosomal 4 275350 Transcobalamin II deficiency 7 252011 Mitochondrial complex II deficiency 4 250940 Homocystinuria-megaloblastic anemia, cblG complementation type 7 611126 Acyl-Coa Dehydrogenase Family, Member 9, Deficiency Of 4 615440 Combined oxidative phosphorylation
Load more

Recommended publications
  • Ovulation-Selective Genes: the Generation and Characterization of an Ovulatory-Selective Cdna Library
    531 Ovulation-selective genes: the generation and characterization of an ovulatory-selective cDNA library A Hourvitz1,2*, E Gershon2*, J D Hennebold1, S Elizur2, E Maman2, C Brendle1, E Y Adashi1 and N Dekel2 1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA 2Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel (Requests for offprints should be addressed to N Dekel; Email: [email protected]) *(A Hourvitz and E Gershon contributed equally to this paper) (J D Hennebold is now at Division of Reproductive Sciences, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon 97006, USA) Abstract Ovulation-selective/specific genes, that is, genes prefer- (FAE-1) homolog, found to be localized to the inner entially or exclusively expressed during the ovulatory periantral granulosa and to the cumulus granulosa cells of process, have been the subject of growing interest. We antral follicles. The FAE-1 gene is a -ketoacyl-CoA report herein studies on the use of suppression subtractive synthase belonging to the fatty acid elongase (ELO) hybridization (SSH) to construct a ‘forward’ ovulation- family, which catalyzes the initial step of very long-chain selective/specific cDNA library. In toto, 485 clones were fatty acid synthesis. All in all, the present study accom- sequenced and analyzed for homology to known genes plished systematic identification of those hormonally with the basic local alignment tool (BLAST). Of those, regulated genes that are expressed in the ovary in an 252 were determined to be nonredundant.
    [Show full text]
  • Mapping Influenza-Induced Posttranslational Modifications On
    viruses Article Mapping Influenza-Induced Posttranslational Modifications on Histones from CD8+ T Cells Svetlana Rezinciuc 1, Zhixin Tian 2, Si Wu 2, Shawna Hengel 2, Ljiljana Pasa-Tolic 2 and Heather S. Smallwood 1,3,* 1 Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USA; [email protected] 2 Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99354, USA; [email protected] (Z.T.); [email protected] (S.W.); [email protected] (S.H.); [email protected] (L.P.-T.) 3 Children’s Foundation Research Institute, Memphis, TN 38105, USA * Correspondence: [email protected]; Tel.: +1-(901)-448–3068 Academic Editor: Italo Tempera Received: 10 October 2020; Accepted: 2 December 2020; Published: 8 December 2020 Abstract: T cell function is determined by transcriptional networks that are regulated by epigenetic programming via posttranslational modifications (PTMs) to histone proteins and DNA. Bottom-up mass spectrometry (MS) can identify histone PTMs, whereas intact protein analysis by MS can detect species missed by bottom-up approaches. We used a novel approach of online two-dimensional liquid chromatography-tandem MS with high-resolution reversed-phase liquid chromatography (RPLC), alternating electron transfer dissociation (ETD) and collision-induced dissociation (CID) on precursor ions to maximize fragmentation of uniquely modified species. The first online RPLC separation sorted histone families, then RPLC or weak cation exchange hydrophilic interaction liquid chromatography (WCX-HILIC) separated species heavily clad in PTMs. Tentative identifications were assigned by matching proteoform masses to predicted theoretical masses that were verified with tandem MS. We used this innovative approach for histone-intact protein PTM mapping (HiPTMap) to identify and quantify proteoforms purified from CD8 T cells after in vivo influenza infection.
    [Show full text]
  • Next Generation Sequencing Panels for Disorders of Sex Development
    Next Generation Sequencing Panels for Disorders of Sex Development Disorders of Sex Development – Overview Disorders of sex development (DSDs) occur when sex development does not follow the course of typical male or female patterning. Types of DSDs include congenital development of ambiguous genitalia, disjunction between the internal and external sex anatomy, incomplete development of the sex anatomy, and abnormalities of the development of gonads (such as ovotestes or streak ovaries) (1). Sex chromosome anomalies including Turner syndrome and Klinefelter syndrome as well as sex chromosome mosaicism are also considered to be DSDs. DSDs can be caused by a wide range of genetic abnormalities (2). Determining the etiology of a patient’s DSD can assist in deciding gender assignment, provide recurrence risk information for future pregnancies, and can identify potential health problems such as adrenal crisis or gonadoblastoma (1, 3). Sex chromosome aneuploidy and copy number variation are common genetic causes of DSDs. For this reason, chromosome analysis and/or microarray analysis typically should be the first genetic analysis in the case of a patient with ambiguous genitalia or other suspected disorder of sex development. Identifying whether a patient has a 46,XY or 46,XX karyotype can also be helpful in determining appropriate additional genetic testing. Abnormal/Ambiguous Genitalia Panel Our Abnormal/Ambiguous Genitalia Panel includes mutation analysis of 72 genes associated with both syndromic and non-syndromic DSDs. This comprehensive panel evaluates a broad range of genetic causes of ambiguous or abnormal genitalia, including conditions in which abnormal genitalia are the primary physical finding as well as syndromic conditions that involve abnormal genitalia in addition to other congenital anomalies.
    [Show full text]
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • Towards Mutation-Specific Precision Medicine in Atypical Clinical
    International Journal of Molecular Sciences Review Towards Mutation-Specific Precision Medicine in Atypical Clinical Phenotypes of Inherited Arrhythmia Syndromes Tadashi Nakajima * , Shuntaro Tamura, Masahiko Kurabayashi and Yoshiaki Kaneko Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Gunma, Japan; [email protected] (S.T.); [email protected] (M.K.); [email protected] (Y.K.) * Correspondence: [email protected]; Tel.: +81-27-220-8145; Fax: +81-27-220-8158 Abstract: Most causal genes for inherited arrhythmia syndromes (IASs) encode cardiac ion channel- related proteins. Genotype-phenotype studies and functional analyses of mutant genes, using heterol- ogous expression systems and animal models, have revealed the pathophysiology of IASs and enabled, in part, the establishment of causal gene-specific precision medicine. Additionally, the utilization of induced pluripotent stem cell (iPSC) technology have provided further insights into the patho- physiology of IASs and novel promising therapeutic strategies, especially in long QT syndrome. It is now known that there are atypical clinical phenotypes of IASs associated with specific mutations that have unique electrophysiological properties, which raises a possibility of mutation-specific precision medicine. In particular, patients with Brugada syndrome harboring an SCN5A R1632C mutation exhibit exercise-induced cardiac events, which may be caused by a marked activity-dependent loss of R1632C-Nav1.5 availability due to a marked delay of recovery from inactivation. This suggests that the use of isoproterenol should be avoided. Conversely, the efficacy of β-blocker needs to be examined. Patients harboring a KCND3 V392I mutation exhibit both cardiac (early repolarization syndrome and Citation: Nakajima, T.; Tamura, S.; paroxysmal atrial fibrillation) and cerebral (epilepsy) phenotypes, which may be associated with a Kurabayashi, M.; Kaneko, Y.
    [Show full text]
  • The Counsyl Foresight™ Carrier Screen
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • The Genetic Basis for Skeletal Diseases
    insight review articles The genetic basis for skeletal diseases Elazar Zelzer & Bjorn R. Olsen Harvard Medical School, Department of Cell Biology, 240 Longwood Avenue, Boston, Massachusetts 02115, USA (e-mail: [email protected]) We walk, run, work and play, paying little attention to our bones, their joints and their muscle connections, because the system works. Evolution has refined robust genetic mechanisms for skeletal development and growth that are able to direct the formation of a complex, yet wonderfully adaptable organ system. How is it done? Recent studies of rare genetic diseases have identified many of the critical transcription factors and signalling pathways specifying the normal development of bones, confirming the wisdom of William Harvey when he said: “nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path”. enetic studies of diseases that affect skeletal differentiation to cartilage cells (chondrocytes) or bone cells development and growth are providing (osteoblasts) within the condensations. Subsequent growth invaluable insights into the roles not only of during the organogenesis phase generates cartilage models individual genes, but also of entire (anlagen) of future bones (as in limb bones) or membranous developmental pathways. Different mutations bones (as in the cranial vault) (Fig. 1). The cartilage anlagen Gin the same gene may result in a range of abnormalities, are replaced by bone and marrow in a process called endo- and disease ‘families’ are frequently caused by mutations in chondral ossification. Finally, a process of growth and components of the same pathway.
    [Show full text]
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol
    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • Saethre-Chotzen Syndrome
    Saethre-Chotzen syndrome Authors: Professor L. Clauser1 and Doctor M. Galié Creation Date: June 2002 Update: July 2004 Scientific Editor: Professor Raoul CM. Hennekam 1Department of craniomaxillofacial surgery, St. Anna Hospital and University, Corso Giovecca, 203, 44100 Ferrara, Italy. [email protected] Abstract Keywords Disease name and synonyms Excluded diseases Definition Prevalence Management including treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract Saethre-Chotzen Syndrome (SCS) is an inherited craniosynostotic condition, with both premature fusion of cranial sutures (craniostenosis) and limb abnormalities. The most common clinical features, present in more than a third of patients, consist of coronal synostosis, brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, broad halluces, and clinodactyly. The estimated birth incidence is 1/25,000 to 1/50,000 but because the phenotype can be very mild, the entity is likely to be underdiagnosed. SCS is inherited as an autosomal dominant trait with a high penetrance and variable expression. The TWIST gene located at chromosome 7p21-p22, is responsible for SCS and encodes a transcription factor regulating head mesenchyme cell development during cranial tube formation. Some patients with an overlapping SCS phenotype have mutations in the FGFR3 (fibroblast growth factor receptor 3) gene; especially the Pro250Arg mutation in FGFR3 (Muenke syndrome) can resemble SCS to a great extent. Significant intrafamilial
    [Show full text]
  • The Genetic Heterogeneity of Brachydactyly Type A1: Identifying the Molecular Pathways
    The genetic heterogeneity of brachydactyly type A1: Identifying the molecular pathways Lemuel Jean Racacho Thesis submitted to the Faculty of Graduate Studies and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Biochemistry Specialization in Human and Molecular Genetics Department of Biochemistry, Microbiology and Immunology Faculty of Medicine University of Ottawa © Lemuel Jean Racacho, Ottawa, Canada, 2015 Abstract Brachydactyly type A1 (BDA1) is a rare autosomal dominant trait characterized by the shortening of the middle phalanges of digits 2-5 and of the proximal phalange of digit 1 in both hands and feet. Many of the brachymesophalangies including BDA1 have been associated with genetic perturbations along the BMP-SMAD signaling pathway. The goal of this thesis is to identify the molecular pathways that are associated with the BDA1 phenotype through the genetic assessment of BDA1-affected families. We identified four missense mutations that are clustered with other reported BDA1 mutations in the central region of the N-terminal signaling peptide of IHH. We also identified a missense mutation in GDF5 cosegregating with a semi-dominant form of BDA1. In two families we reported two novel BDA1-associated sequence variants in BMPR1B, the gene which codes for the receptor of GDF5. In 2002, we reported a BDA1 trait linked to chromosome 5p13.3 in a Canadian kindred (BDA1B; MIM %607004) but we did not discover a BDA1-causal variant in any of the protein coding genes within the 2.8 Mb critical region. To provide a higher sensitivity of detection, we performed a targeted enrichment of the BDA1B locus followed by high-throughput sequencing.
    [Show full text]